Bengaluru: SII launches HPV-cancer awareness campaign
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
15 hours ago
- Hindustan Times
Skin tags vs. warts vs. moles: How to distinguish these 3 skin conditions? Dermat shares a guide
Skin growths are common, but recognising their early signs is crucial for timely diagnosis and proper treatment. In an interview with HT Lifestyle, Dr. Sneha Shah, oculoplastic and facial aesthetic surgeon said, 'Skin growth is a common condition, but not all bumps are the same. Which is why it is vital to understand the difference between skin tags, warts and moles for timely treatment and for feeling more confident.' Also read | Seborrheic keratosis: Causes, symptoms, diagnosis and treatment of wart or mole-like benign skin tumours Here's how to distinguish between skin tags, moles and warts.(Freepik) Appearance: It looks soft and fresh-colored or slightly darker and is often hanging off the skin by a thin stalk. Texture: It is smooth and slightly wrinkled and feels soft to touch. Location: Mostly appears on the eyelids, neck, underarms, breasts, or groin folds—areas where skin rubs against skin. Cause: Friction, hormonal changes (common in pregnancy), obesity, and insulin resistance. Are they dangerous?: No. Skin tags are benign in nature and usually feel painless but might get irritated by jewellery or clothing. Treatment: Can be removed quite easily by a doctor using a cautery, freezing, or snipping under sterile conditions. Also read | Skin infections to watch out for in gym, tips to prevent yourself from contracting them Skin tags are benign in nature.(Unsplash) 2. Warts: Appearance: They are rough, raised bumps that have a cauliflower-like surface and might have black dots or clotted blood vessels. Texture: they are rather firm and irregular. Location: Hands, feet (plantar warts), knees, and other areas prone to cuts or minor trauma. Cause: Human Papillomavirus (HPV) infection, which can spread through skin contact or shared surfaces. Are they dangerous?: They are usually benign but can be contagious and might spread. Treatment: Can be treated using cryotherapy, laser treatment, or minor surgery. Avoid self-removal due to risk of spread. 3. Moles (nevi): Appearance: They are usually flat/ raised and brown, black or skin-colored spots. Usually are round or oval with regular borders. Texture: It can be smooth, rough, or even hairy. Location: Can be found anywhere on the body. Cause: Clusters of pigmented cells; genetic or due to sun exposure. Are they dangerous?: Mostly benign, but new or changing moles may signal melanoma. Also read | Obesity's effect on skin: Doctor shares 7 skin conditions to be aware of and prevention tips to stay safe Red flags: Asymmetry, border irregularity, color variation, diameter >6mm, and evolving shape or size. Treatment: Suspicious moles should be examined immediately, and the removal might be cosmetic or precautionary. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
India Gazette
a day ago
- India Gazette
BE to manufacture HPV9 vaccine for India, UNICEF and PAHO tender markets
Hyderabad (Telangana) [India], July 1 (ANI): Jiangsu Recbio Technology Company Limited ( announced that they have entered into a licensing cooperation agreement, and have commenced the technology transfer of their Recombinant 9-valent HPV (HPV9) vaccine, REC603, to Biological E. Limited (BE), a leading Indian vaccine and pharmaceutical company. Recbio will provide BE with Drug Substance (DS) and transfer technology to formulate, fill, and package vaccines. It will also include technology transfer for DS production at an appropriate time in the future. According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF & PAHO tenders in other markets. The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. HPV is a group of over 200 known viruses, some of which are classified as high-risk due to their potential to cause cancer. While most HPV infections are controlled by the body's immune system, persistent infections with high-risk HPV types can lead to cervical cancer and other malignancies affecting the vulva, vagina, mouth, throat, penis, and anus. In 2019 alone, HPV was linked to an estimated 620,000 cancer cases in women and 70,000 in men. Preventive vaccination, alongside HPV screening and treatment of pre-cancerous lesions, is a key strategy in reducing the global burden of HPV-related cancers. Cervical cancer is the fourth leading cause of cancer-related deaths among women worldwide. The 9-valent HPV vaccine is effective in preventing around 90 percent of cervical cancer and 90 percent of anal and genital warts. Recbio's core product, REC603, is for people ranging from 9 to 45 years old and is currently in the crucial Phase III clinical trials in China. Following the signing of the technology license agreement, Recbio has begun transferring the necessary technical knowledge, materials, and expertise to BE to produce the HPV9 vaccine. Recbio will continue to support BE in clinical development and regulatory approvals to ensure a seamless transition. This collaboration comes at a crucial time, as the global demand for cervical cancer prevention is at an all-time high. By leveraging BE's advanced manufacturing capabilities, this partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets. BE will begin large-scale manufacturing of the HPV9 vaccine once the Technology transfer is completed. This collaboration marks a significant milestone for Recbio in entering the Indian and international markets, highlighting its potential in the innovative vaccine field. Dr. Liu Yong, Founder, Chairman, and CEO of Recbio, stated, 'We are delighted to collaborate with Biological E. Limited. This cooperation is another significant progress for Recbio in expanding into international markets., We will work together with our Indian partner to accelerate the launch process of the HPV9 vaccine in India, and jointly make greater contributions to global public health.' Mahima Datla, Managing Director, Biological E. Limited, said: 'We are pleased to partner with Recbio to bring the HPV9 vaccine to India and other countries. This collaboration aligns with our commitment to improving global health by making essential vaccines more accessible and affordable as well as to promote a lasting legacy of innovation and stewardship. We, along with Recbio, are committed to creating a healthier and more robust future by ensuring that this life-saving vaccine is delivered to those who need it the most.' (ANI)
Time of India
a day ago
- Time of India
Biological E, Recbio ink pact to make HP9 vax in India
HYDERABAD: Biopharma company Biological E Ltd (BE) entered into a licensing cooperation agreement with Chinese biopharma player Jiangsu Recbio Technology Company Limited for the latter's recombinant 9-valent Human Papillomavirus (HPV9) vaccine, REC603. The HPV9 vaccine has been designed to protect against nine types of HPV, including those responsible for cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. As part of the agreement, Recbio will provide BE with the drug substance (DS) and transfer technology to formulate, fill, and package vaccines. BE will get exclusive rights to commercialise the vaccine in India and also participate in United Nations Children's Fund (UNICEF) and Pan American Health Organisation (PAHO) tenders in other markets. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad Get the latest lifestyle updates on Times of India, along with Doctor's Day 2025 , messages and quotes!
